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Abstract: Chitin and its derivatives—as a potential resource as well as multiple functional 
substrates—have  generated  attractive  interest  in  various  fields  such  as  biomedical, 
pharmaceutical,  food and environmental industries, since the first isolation of chitin in 
1811. Moreover, chitosan and its chitooligosaccharides (COS) are degraded products of 
chitin through enzymatic and acidic hydrolysis processes; and COS, in particular, is well 
suited for potential biological application, due to the biocompatibility and nontoxic nature 
of chitosan. In this review, we investigate the current bioactivities of chitin derivatives, 
which are all correlated with their biomedical properties. Several new and cutting edge 
insights here may provide a molecular basis for the mechanism of chitin, and hence may 
aid its use for medical and pharmaceutical applications. 
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1. Introduction 
Since chitin (C8H13O5N)n was first isolated and characterized from mushrooms, the earliest known 
polysaccharide, by  French chemist Henri Braconnot in 1811 [1],  it has been discovered to be the 
second most abundant natural biopolymer in the world [2–4], amounting in marine biomass alone to 
approximately  106–107  tons.  Chitin  is  a  long-chain  homopolymer  of  N-acetyl-D-glucosamine 
(GlcNAc), (1–4)-linked 2-acetamido-2-deoxy-β-D-glucan, a derivative of glucose. Strong acids can 
split the chitin, water-insoluble polymer, into acetic acid and chitosan, and chitin can be processed 
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further into two main derivatives of chitosan and amino glucose through many nonspecific enzymes, 
such  as  cellulases,  lipases,  proteases  and  chitosanases  [5,6].  Notably,  chitosan  is  a  nontoxic 
biopolymer produced by the deacetylation of chitin, and currently chitosan and its oligosaccharides 
have received considerable attention due to their biological activities and properties in commercial 
applications.  During  the  last  few  decades,  as  a  source  of  bioactive  material,  chitosan  and 
chitooligosaccharides, which are degradation products of chitin or chitosan produced by enzymatic or 
acidic hydrolysis, were introduced into a variety of biomedicals including wound dressings and drug 
delivery systems [7,8], and the food and chemical industries [9–12]. Chitin and its derivatives have 
delivered biological potential for a wide range of applications such as in the food and medical field 
[13–16], agriculture [17] and aquaculture [18,19], dental [20,21] and cosmetics [22,23], wastewater 
[24,25] and membranes [26,27] . 
This review aims to analyze the most recent advances in biological applications of chitin and its 
derivatives,  particularly  those related to anti-inflammatory  and  antioxidant activities,  antimicrobial 
effects,  immunity-enhancing  as  well  as  antitumor  effects  and  drug  delivery,  in  the  field  of   
biological medicine. 
2. Antioxidant Activity 
Hydrogen  peroxide,  hydroxyl  radical  and  superoxide  anion  called  reactive  oxygen  species 
(ROS) [28] are generated during normal metabolism and oxidize biomolecules, such as lipids, proteins, 
carbohydrates and DNA, ultimately leading to oxidative stress. However, cells produce antioxidants 
such  as  catalase,  superoxide  dismutase,  glutathione  peroxidase  and  thioredoxins  as  a  part  of  the 
cellular  defense  system  against  ROS-mediated  cellular  injury  [28].  When  the  cellular  defense 
mechanisms  are  unable  to  deal  with  excessive  generation  of  ROS,  this  oxidative  stress  has  been 
reported  to  induce  various  pathogenic  processes  including  aging,  cancer,  wrinkle  formation, 
rheumatoid arthritis and inflammation [29–33]. Therefore, antioxidants including vitamin C and E play 
an important role in maintaining balance between the oxidative and reductive state inside the body. 
Among  these  antioxidants,  chitins—widely  distributed  among  invertebrates  and  crustaceans  as 
structural  material  in  their  exoskeletons  and  fungal  cell  walls—have  shown  important  biological 
antioxidant effect that has potentials for a wide variety of applications [34]. However, chitin is an 
insoluble polymer in water, which is the major limiting factor for its utilization in living systems. 
Therefore, it is important to produce soluble chitin or chitosan by hydrolysis. In recent years, two 
kinds  of  chitin  oligosaccharides  or  N-acetyl  chito-oligosaccharides  (NA-COSs)  with  different 
molecular weights [35] produced from crab chitin hydrolysis was evaluated in live cells. Two kinds 
of NA-COSs  with  molecular  weights  (M.W.)  of  1–3 kDa  (NA-COS  1–3 kDa)  and  below  1 kDa   
(NA - COS < 1 kDa) exhibited an inhibitory effect against DNA and protein oxidation. In addition, 
intracellular glutathione (GSH) level and direct intracellular radical scavenging effect were increased 
in the presence of them in mouse macrophages (RAW 264.7) and exerted an inhibitory effect against 
cellular oxidative stress. In particular, NA-COS 1–3 kDa was more effective than NA-COS < 1 kDa in 
protein oxidation and production of intracellular free radicals in live cells [13]. Furthermore, it was 
reported  that  chitin  oligosaccharides  (NA-COS;  M.W.  229.21–593.12  Da)  produced  by 
acidic hydrolysis of crab chitin exert the cellular antioxidant effects. In addition, the inhibitory effect Int. J. Mol. Sci. 2010, 11                  
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of NA-COS on myeloperoxidase (MPO) activity in human myeloid cells (HL-60) and oxidation of 
DNA and protein were identified in mouse macrophages. Moreover, their direct radical scavenging 
effect of intracellular hydrogen peroxide and intracellular glutathione (GSH) level were demonstrated, 
suggesting that NA-COS act as potent antioxidants in live cells [3]. Previous study also showed how 
disease  resistance  and  ROS  metabolism  in  harvested  navel  oranges  are  affected  by  chitosan.  Its 
treatment effectively not only enhanced the activities of peroxidase and superoxide dismutase, and 
levels of glutathione and hydrogen peroxide, but also inhibited the activity of catalase and the decrease 
of ascorbate content during navel orange fruit storage, suggesting that chitosan treatment could induce 
navel orange fruit disease resistance by regulating the H2O2 levels, antioxidant enzyme and ascorbate–
glutathione cycle [36]. Furthermore, it was demonstrated that COS smaller than 1 kDa suppressed the 
generation  of  intracellular  radical  species  in  B16F1,  a  murine  melanoma  cell  line,  suggesting 
prevention of oxidative stress related disease. In addition, induction of intracellular glutathione (GSH) 
level was increased in the presence of COS, which exhibited a protective effect on oxidative damage of 
genomic DNA independent of molecular weight [37]. Chitosan also has an in vivo stimulatory effect 
on both nitric oxide production and modulates peroxide production [38]. The protective effects of COS 
against hydrogen peroxide-induced oxidative damage were also evaluated in human umbilical vein 
endothelial cells (HUVEC, ECV304 cells). In addition to a marked decrease in intracellular ROS level, 
COS also exerted preventive effects on the production of lipid peroxidation such as malondialdehyde, 
restoring  activities  of  endogenous  antioxidants  including  superoxide  dismutase  and  glutathione 
peroxidase, along with the capacity of increasing levels of nitric oxide and nitric oxide synthase. It was 
also  demonstrated  that COS  can  effectively  protect  HUVEC  against  oxidative  stress  by  hydrogen 
peroxide, which might be of importance in the treatment of cardiovascular diseases [39]. In addition, 
COSs (M.W.1500, DD. 90%) protect against Cu(II) induced neurotoxicity in primary cortical neurons 
by interfering with an increase in intracellular ROS [40]. Moreover, COS of four different molecular 
weight ranges (below 1 kDa, 1–3 kDa, 3–5 kDa and 5–10 kDa) were investigated for their ability to 
protect  pancreatic-β  cells  from  damage  induced  by  hydrogen  peroxide.  COS  (500  μg/ml)  with 
molecular  weights  of  3–5  kDa  raised  the  viability  of  hydrogen  peroxide-treated  cells  by  58.46% 
compared with the hydrogen peroxide alone group [41]. It was also described that COS is able to 
protect  hydrogen  peroxide-induced  oxidative  stress  on  human  embryonic  hepatocytes  (L02  cells), 
suggesting that COS  might  be useful  in  a  clinical  setting during the treatment  of oxidative stress 
related liver damage [42]. Administration of chitosans with low molecular weight was reported to 
inhibit  neutrophil  activation  and  oxidation  of  serum  albumin  commonly  observed  in  patients 
undergoing hemodialysis, resulting in reduction of oxidative stress associated with uremia [43]. On the 
other  hand,  the  cellular  antioxidant  effects  of  carboxylated  chitooligosaccharides  (CCOS),  a 
chemically modified derivative of  COS,  were evaluated  by the  ability to inhibit lipid and protein 
oxidation. Radical-mediated oxidation of cell membrane lipids and proteins was inhibited by CCOS 
that reduced the level of lipid hydroperoxides and carbonyl carbon content in mouse macrophages. 
Further, CCOS inhibited myeloperoxidase activity in human myeloid cells, suggesting the indirect 
possibility of inhibiting generation of ROS such as superoxide radicals, H2O2 and HOCl [44].   
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3. Anti-inflammatory Effects 
Although a number of studies have widely investigated the effects of chitin,  chitosan and their 
derivatives, few investigating anti-inflammatory activity have recently been published. Inflammation is 
a physiological body immune response against pathogens, toxic chemicals or physical injury. While 
acute inflammation is a short-term normal response that usually causes tissue repair by recruitment of 
leukocytes  to  the  damaged  region,  chronic  inflammation  is  a  long-term  pathological  response 
involving  induction  of  own  tissue  damage  by  matrix  metalloproteinases  (MMPs)  [45,46].  It  is 
generally well known that chronic inflammation is related to periodontal disease, hepatitis, arthritis, 
gastritis and colitis. The most important factor in chronic inflammation has been known to be the nuclear 
factor-kappa B (NF-κB) transcription factor that plays a critical role in regulating genes involved in 
immune responses [47]. NF-κB is known to regulate inflammatory genes encoding pro-inflammatory 
cytokines,  adhesion  molecules,  cyclooxygenase-2  (COX-2)  and  inducible  nitric  oxide  synthase 
(iNOS) [48,49]. In particular, current approaches to the treatment of inflammation rely on the selective 
inhibition  of  COX-2  activity  responsible  for  producing  prostanoids,  not  COX-1.  Non-steroidal   
anti-inflammatory  drugs  (NSAIDs)  are  the  most  widely  prescribed  drug  for  treatment  of  many 
inflammatory  diseases.  However,  they  display  a  high  incidence  of  gastric,  renal  and  hepatic  side 
effects. In recent years, it has been reported that chronic inflammation is associated with an increased 
risk of malignant transformation [50]. This is because phagocytic leukocytes in chronic inflammatory 
processes produce large amounts of reactive metabolites of oxygen and nitrogen that induce oxidative 
stress and lead to oxidation of fatty acids and proteins in cell membrane, thus impairing their normal 
function. Although the anti-inflammatory effects of chitin and its derivatives have been rarely reported, 
in recent years data has been accumulating. First of all, it was found that chitin is a size-dependent 
regulator
 of inflammation [51]. In this study, while both intermediate-sized chitin and small chitin 
stimulates  TNF  production  in  murine  peritoneal  macrophages,  large  chitin  fragments
  are  inert, 
Furthermore,  it  was  found  that  chitin  stimulates  the  expression  of  TLR2,  dectin-1,  the  mannose 
receptor  and  inflammatory  cytokines,  differentially  activated
  NF-κB  and  spleen  tyrosine  kinase. 
Ngo et al. (2009) demonstrated that chitin oligosaccharides can inhibit myeloperoxidase activity in 
human myeloid cells and oxidation of DNA and protein in mouse macrophages [13]. Chitosan was 
confirmed to partially inhibit the secretion of both IL-8 and TNF-α from mast cells, demonstrating that 
water-soluble chitosan has the potential to reduce the allergic inflammatory response [52]. Since mast 
cells are necessary for allergic reactions and have been implicated in a number of neuroinflammatory 
diseases,  chitosan  nutraceuticals  may help  to  prevent  or alleviate some of these complications.  In 
another  study,  it  was  demonstrated  that  chitooligosaccharides  enhanced  migration  of  the  mouse 
peritoneal macrophages into inflammatory areas [53]. LPS-stimulated TNF-α and IL-6 secretion was 
found to be inhibited in the presence of chitosan oligosaccharide in RAW 264.7 cells [54], suggesting 
that chitosan oligosaccharide may possess an anti-inflammatory effect via the inhibition of TNF-α in 
the LPS-stimulated inflammation. These functions of chitosan to exert anti-inflammatory effect could 
be unilized in the nutraceutical industry as well as in functional foods for prevention and alleviation of 
inflammatory diseases. In addition, it was reported that chitosan promotes phagocytosis and production 
of  osteopontin  and  leukotriene  B  by  polymorphonuclear  leukocytes,  production  of  interleukin-1, 
transforming growth factor b1 and platelet-derived growth factor by macrophages, and production of Int. J. Mol. Sci. 2010, 11                  
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interleukin-8 by fibroblasts, enhancing immune responses [55]. The effect of chitin, chitosan and their 
derivatives on MMPs related to chronic inflammation is an interesting topic presently. MMPs are a 
family of secreted or transmembrane endopeptidases that degrade extracellular matrix components. It 
was  described  that  chitooligosaccharides  inhibit  activation  and  expression  of  MMP-2  in  primary 
human dermal fibroblasts [56]. In particular, hydrolysed chitosans with molecular weights as low as   
3–5 kDa displayed the highest inhibitory effect on MMP-2. Moreover, the inhibitory effect might be 
described by the effective chelating capacity of chitosan for Zn
2+ as a cofactor of MMP-2. Based on 
these findings, as a result of elucidation of the relationship between their activities and structures, 
atomic force microscopy demonstrated a direct molecular interaction between MMP-2 and chitosan. 
Affinity chromatography revealed a high binding-specificity of MMP-2 to chitosan, and a colorimetric 
assay suggested a non-competitive inhibition of MMP-2 by chitosan [57]. 
4. Antimicrobial Effects 
Chitosan and its derivatives have widespread applications in agriculture, medicine, environment, 
food, etc. The antimicrobial activity of chitin, chitosan and their derivatives against different groups of 
microorganisms, such as bacteria, yeast and fungi has received considerable attention in recent years. 
In  particular,  chitosan  can  also  be  used  as  an  antimicrobial  film  to  cover  fresh  fruits  and 
vegetables [58]. Chitosan, which is a deacetylated form of chitin, has been investigated for numerous 
antimicrobial  activities.  In  particular,  water-soluble  chitosan  derivatives  were  evaluated  for  their 
antimicrobial  activity  [59].  The  actual  mechanism  of  antimicrobial  activity  of  chitosan  and  its 
derivatives is not yet fully understood but has been suggested to involve cell lysis, breakdown of the 
cytoplasmic membrane barrier and the chelation of trace metal cations by the chitosan [60–64]. In the 
killing of gram-negative bacteria, a cationic chitosan must interact with both bacterial cell envelope 
membranes. The antibacterial effect of chitosan is higher than that of chitin because chitosan possesses 
a  number  of  polycationic  amines  which  can  interact  with  the  negatively  charged  residues  of 
carbohydrates, lipids and proteins located on the cell surface of bacteria, which subsequently inhibit 
the growth of bacteria. In addition, because of the positive charge on the C-2 of the glucosamine 
monomer at pH values below 6, chitosan is more soluble and has a better antimicrobial activity than 
chitin [65]. The antibacterial effects of COS have been known to be dependent on their degree of 
polymerization  or  molecular  weight.  In  addition,  the  water-soluble  chitooligosaccharides  may  be 
advantageous as antibacterial agents in in vivo systems compared to water-insoluble chitosan. These 
variations in preparation methods are likely to result in differences in the deacetylation degree, the 
distribution of acetyl groups, the chain length and the conformational structure of chitosan [66] and 
will thereby have an influence on the solubility, the antimicrobial activity and other properties. The 
antibacterial  effect  of  three  kinds  of  COS  with  relatively  higher  molecular  weight  (HMWCOS), 
medium molecular weight (MMWCOS), and lower molecular weight (LMWCOS), respectively, was 
evaluated against various microorganisms. The molecular weight of COS is critical for microorganism 
inhibition and required higher than 10,000 Da. Generally, the COS have more effective activity against 
pathogens than nonpathogens, except in the case of lactic acid bacteria [67]. In addition to chitosan, 
several  chitosan  derivatives  such  as  acid-free-water  soluble  chitosan  [68]  and  quaternary  N-alkyl 
chitosan  [69]  were  reported  to  exert  antimicrobial  effect.  The  antimicrobial  activity  of  chitosan Int. J. Mol. Sci. 2010, 11                  
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depends on several factors such as the kind of chitosan (deacetylation degree or molecular weight), the 
pH  of  the  medium,  the  temperature,  the  presence  of  several  food  components  and  so  forth.  The 
mechanism of the antimicrobial activity has not been fully elucidated yet, but several hypotheses have 
been postulated. The most feasible hypothesis is a change in cell permeability due to interactions 
between the positive charges of chitosan and the negative charges on the cell surface. This interaction 
between  positively  charged  chitosan  molecules  and  negatively  charged  microbial  cell  membranes 
results in the leakage of intracellular constituents. In addition, it can be suggested that chitosan and its 
derivatives not only bind to bacterial genes but also chelate metals such as calcium, magnesium and 
zinc  ions,  leading  to  the  inhibition  of  transcription  and  translation.  Therefore,  an  antibacterial 
mechanism of chitosan and its derivatives can be described to be exerted by above mechanisms. 
5. Immuno-Stimulating and Anticancer Effects 
In recent years, it was revealed that the tumor inhibitory effect of COS is probably related to their 
induction of lymphocyte cytokines through increasing T-cell proliferation (Figure 1). Basically, the 
antitumor mechanism of COS is enhanced by acquired immunity via accelerating T-cell differentiation 
to increase cytotoxicity and maintain T-cell activity [70]. Maeda and Kimura examined the antitumor 
effects of various low-molecular weight chitosans, such as water-soluble 21- or 46-kDa molecules with 
low viscosity, produced by enzymatic hydrolysis of over 650-kDa chitosan, which displayed decreased 
tumor growth and final tumor weight in sarcoma 180-bearing mice due to increase of natural killer cell 
activity  [71,72].  The  results  indicate  the  low-molecular-weight  water-soluble  chitosans  and 
oligochitosans might be useful in preventing tumor growth, partly through enhancing cytotoxic activity 
against tumors as an immunomodulator [73]. In transdermal delivery of baicalin for an useful drug for 
the treatment of skin disease, low-molecular-weight chitosans can improve its permeation through 
mouse skin [74]. In addition, they seem to activate macrophages via the production of cytokines such 
as interferon (IFN)-γ, interleukin (IL)-12 or -18 from the intraepithelial lymphocytes. In examination 
of  the  anticancer  activity  of  chitosan  derivatives,  there  was  no  clear  information  describing  the 
relationship between charge properties and their observed activities. In recent years, in several cell 
lines, one research group observed that cancer-cell viability was significantly reduced regardless of the 
positive or negative charge of differently charged COS derivatives [75]. Moreover, COS significantly 
inhibited  human  hepatocellular  (HepG2)  carcinoma  cell  proliferation  and  down-regulated  cell   
cycle-related gene expressions with decreased DNA content and up-regulation of p21 in vitro. In in 
vivo observations, COS inhibited tumor growth of HepG2 and Lewis lung carcinoma xenografts and 
lung tumor nodules as well as lung metastasis [76]. Quan et al. suggest that COS act as inhibitors of 
heparanase,  which  is  a  β-endoglucuronidase,  and  assist  tumor  invasion,  metastasis  and   
angiogenesis [77].   
Other  chemically  modified  structures,  aminoderivatized  COSs,  such  as  aminoethyl-,  dimethyl 
aminoethyl-  and diethyl aminoethyl-COS,  not  only  significantly induce cell death  but  also  inhibit 
proliferation  of  human  gastric  adenocarcinoma  cells  [78].  This  report  shows  that  water-soluble 
aminoderivatized COS might be able to serve as valuable cancer chemopreventive agents. COS could 
also suppress tumor angiogenesis in vivo and in vitro [79,80] through blocking migration of endothelial 
cells induced by nitric oxide [81,82].   Int. J. Mol. Sci. 2010, 11                  
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Figure  1.  Chitooligosaccharides  (COS)  can  display  anti-tumorigenic  activity  through 
immunomodulation. 
 
6. Application in Drug Delivery System 
To provide anticancer chemotherapy, chitosan is attracting increasing attention as drug and gene 
carriers due to its excellent biocompatibility, biodegradability, and nontoxicity [83,84]. Chitosan has 
an important role in delivery of drugs, with the potential to improve drug absorption and stabilize drug 
components to increase drug targeting. In addition, as a potential gene deliverer, chitosan can protect 
DNA  and  increase  the  expression  period  of  genes.  Chitin  or  chitosan  derivatives,  which  were 
conjugated with some kinds of anticancer agents, can execute better anticancer effects with a decrease 
of  side  effects  and  gradual  release  of  free  drug  in  the  cancer  tissues.  Furthermore,  chitosan 
nanoparticles were synthesized and applied for in vivo antitumor activity [85–87]. On the other hand, 
for ocular drug delivery, liposomes coated with low-molecular weight chitosan may be potentially 
applicable to clinic uses [88]. 
Nanoparticles  enable  chitosan  to  elicit  dose-dependent  tumor-weight  inhibition  with  highly 
impressive antitumor efficacy in vivo [88]. The doses and particle quantum size have a great effect on 
their efficacy as drug carriers. In particular, with small particle size and positive surface charge, the 
complex could exhibit higher antitumor activity than other chitosan derivatives [89]. Smaller sized 
particles seem  to  enhance efficacy of the particle-based drug delivery systems  [90–92]. Basically, 
chitosan  nanoparticles  are  produced  with  a  mean  particle  size  ranging  from  40  to  100  nm  and  a 
positive surface charge of about 50 mV [93,94]. To introduce these products into in vitro cell culture Int. J. Mol. Sci. 2010, 11                  
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systems, they should be filtered by a membrane with diameter of 0.45 μm and autoclaved [95]. In in 
vivo animal models, different administration routes of chitosan nanoparticles, such as intravenous (i.v.) 
or  intraperitoneal  injection  (i.p.)  and  oral  administration  (p.o.),  could  exhibit  little  difference  in 
antitumor activities. However, because nanoparticulate systems have been developed to improve the 
blood  circulating  time  and  tumor  targeting  efficacy  of  vincristine,  administration  of  chitosan 
nanoparticles  i.v.  can  contribute  in  vivo  efficacy  to  antitumor  activities  [96,97]  followed  by  a 
prolonged blood half-life of drugs [98]. 
7. Conclusion 
In  recent  years,  chitin  and  its  derivatives—as  a  high  potential  resource  as  well  as  multiple 
functional  substrates—have  generated  attractive  interest  in  various  fields  such  as  biomedical, 
pharmaceutical, food and environmental industries. While chitin is an insoluble polymer in water, 
which is the major limiting factor for its utilization in living systems, COS are more suited to draw 
attention for potentially biological applications due to the biocompatibility and nontoxic nature of 
chitosan. They exert an excellent antioxidant effect as well as antimicrobial effect. In particular, COS 
and  their  derivatives  are  potential  candidates  capable  of  preventing  or  treating  diverse  chronic 
inflammation such as colitis, periodontal disease, hepatitis and gastritis, leading to cancer, and through 
drug delivery system.   
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